Helix BioPharma Corp. announces fiscal 20...( WKN: ...)

WKN: 918 846

AURORA, ON, Oct. 26 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the year ended July 31, 2007.

During the 2007 fiscal year, the Company continued to make progress with its clinical (Topical Interferon Alpha-2b) and pre-clinical (L-DOS47) development programs. The following are selected highlights during the 2007 fiscal year and subsequent to year-end.

HIGHLIGHTS

- Topical Interferon Alpha-2b

- Announced positive Phase II clinical results with Topical

Interferon Alpha-2b in patients with HPV-induced low-grade

squamous intraepithelial lesions ("LSIL")

- Initiated enrollment in Phase II clinical trial with Topical

Interferon Alpha-2b in patients with HPV-induced ano-genital warts

- L-DOS47

- Awarded two U.S. patents for DOS47, a broad anti-cancer

therapeutic candidate

- Presented L-DOS47 findings at the fourth international conference

on "Tumour Microenvironment" in Florence, Italy

- Presented L-DOS47 findings at Keystone Symposia meeting,

"Antibodies as Drugs: From Basic Biology to Clinic"

- Signed L-DOS47 manufacturing agreement with BioVectra DCL

- Financing

- Completed a private placement financing on October 11, 2006 for

gross proceeds of $7,044,500.

- Other

- Shareholders approved management proposals and elected

management's slate of directors at the 2007 annual meeting of

shareholders, following a proxy dispute

- Announced University of Arizona Professor, Kenneth D. Hatch,M.D.,

as medical advisor

- Mr. Jerome F. McElroy resigned as Chairman and Director of the

Company

- Introduced a new company logo as part of our ongoing efforts to<
'/>"/>